In case you missed it, former U.S. Representative for Pennsylvania’s 6th Congressional District Ryan Costello discusses how recent legislation targeting pharmacy benefit companies will raise costs for taxpayers and patients and do nothing to address the root cause of high
The vast majority of employers and public health programs voluntarily work with pharmacy benefit companies to manage pharmacy benefits. So, what happens when a health plan doesn’t use a pharmacy benefit company? A recent Department of Labor (DOL) Office of the
With so many important issues being debated today, there are few topics that health care, legal, and economic experts agree on. But the fact that drug companies are the root cause of high prescription drug prices is one common denominator
In case you missed it, Johnny Garcia, PharmD, Senior Director, Policy at the Pharmaceutical Care Management Association (PCMA), explains the critical role pharmacy benefit companies play in supporting all members of the prescription drug supply chain, including retail pharmacies, in
A simple fact is often lost in the din of the current drug pricing debate going on in Washington D.C. and around the country: Drug companies retain the great majority of the prescription drug dollar. What is the prescription drug
The U.S. House of Representatives is preparing a suspension vote on the Lower Costs, More Transparency Act, which includes many of the controversial, overreaching proposals impacting pharmacy benefits. A recent Washington Examiner article highlighted growing concerns among Members of Congress
“PBMs promote competition in healthcare and help to reduce prices,” said Lawton Robert Burns Hot Off the Presses: University of Pennsylvania Wharton School professor Lawton Robert Burns releases a new book explaining the critical role pharmacy benefit companies play in
In case you missed it, Jason Altmire, former Democratic three-term U.S. Representative from Pennsylvania and current adjunct professor at Texas Tech University, explains why so-called “delinking” proposals would be catastrophic for patients and families’ pocketbooks in a new op-ed in
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association (PCMA), highlights the opportunity Congress now has to get it right on drug pricing reforms in a new op-edpublished in RealClearHealth. He writes: “With
While Big Pharma pushes misguided policies targeting pharmacy benefits as part of a blame game designed to keep prescription drug prices high, former Members of Congress are reminding current lawmakers that they’ve seen this movie before. Congress has considered similar
©2024 PCMA. All Rights Reserved.
